Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

References

• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006;12:1255–91. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006;12:1255–9
   PubMed Web of Science ®Google Scholar
• Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166–812. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166–81
   PubMed Web of Science ®Google Scholar
• Behan MWH, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004;80:155–643. Behan MWH, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004;80:155–64
   PubMed Web of Science ®Google Scholar
• Eshaghian S, Kaul S, Amin S, et al. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med 2007;146:434–414. Eshaghian S, Kaul S, Amin S, et al. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med 2007;146:434–41
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005;112:2946–505. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005;112:2946–50
   PubMed Web of Science ®Google Scholar
• The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for Percutaneous Coronary Interventions. Eur Heart J 2005; 26:804–476. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for Percutaneous Coronary Interventions. Eur Heart J 2005; 26:804–47
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Gibson CM, et al. on behalf of the TRITON-TIMI 38 investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627–357. Wiviott SD, Antman EM, Gibson CM, et al. on behalf of the TRITON-TIMI 38 investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627–35
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096–1048. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096–104
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63:421–309. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63:421–30
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with cloipdogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166–7310. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with cloipdogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166–73
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response. TCT Meeting, October 23-27. Am J Cardiol 2006;98:S20011. Small DS, Farid NA, Payne CD, et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response. TCT Meeting, October 23-27. Am J Cardiol 2006;98:S200
   Web of Science ®Google Scholar
• Saltman DC, Sayer GP, Whicker SD. Co-morbidity in general practice. Postgrad Med J 2005;81:474–8012. Saltman DC, Sayer GP, Whicker SD. Co-morbidity in general practice. Postgrad Med J 2005;81:474–80
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000–2002. Diabetes Care 2005;28:1599–60313. Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000–2002. Diabetes Care 2005;28:1599–603
   PubMed Web of Science ®Google Scholar
• Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004;43:576–8214. Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004;43:576–82
   PubMed Web of Science ®Google Scholar
• Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7:165–8215. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7:165–82
   PubMed Web of Science ®Google Scholar
• Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413–58016. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413–580
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–4117. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–41
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Kline-Rogers E, Fang J, et al. Lack of clopidogrel–CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005;91:23–618. Mukherjee D, Kline-Rogers E, Fang J, et al. Lack of clopidogrel–CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005;91:23–6
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 2003;107:32–719. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 2003;107:32–7
   PubMed Web of Science ®Google Scholar
• Müller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003;108:2195–720. Müller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003;108:2195–7
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475–8421. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475–84
   PubMed Web of Science ®Google Scholar
• Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715–2222. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715–22
   PubMed Web of Science ®Google Scholar
• Klotz U, Kroemer HK. The drug interaction potential of ranitidine: an update. Pharmacol Ther 1991;50:233–4423. Klotz U, Kroemer HK. The drug interaction potential of ranitidine: an update. Pharmacol Ther 1991;50:233–44
   PubMed Web of Science ®Google Scholar
• Merki HS, Witzel L, Walt RP, et al. Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers. Gut 1988;29:81–424. Merki HS, Witzel L, Walt RP, et al. Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers. Gut 1988;29:81–4
   PubMed Web of Science ®Google Scholar
• Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990;12 Suppl 2:S54–6325. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990;12 Suppl 2:S54–63
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Schühlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232–826. Kastrati A, Mehilli J, Schühlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232–8
   PubMed Web of Science ®Google Scholar
• Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:169–7927. Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:169–79
   PubMed Web of Science ®Google Scholar
• Takahashi M, Pang H, Kikuchi A, et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LCMS/MS. 54th ASMS Meeting, Seattle, WA. J Am Soc Mass Spectrom 2006; S52; Abstract nr MP 1128. Takahashi M, Pang H, Kikuchi A, et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LCMS/MS. 54th ASMS Meeting, Seattle, WA. J Am Soc Mass Spectrom 2006; S52;Abstract nr MP 11
   Google Scholar
• Eli Lilly and Company, Study Report H7T-EW-TABS29. Eli Lilly and Company, Study Report H7T-EW-TABS
   Google Scholar
• US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: in vivo drug metabolism/drug interaction studies – study design, data analysis, and recommendations for dosing and labeling. Available at: http://www.fda.gov/cder/guidance/2635fnl.htm. Accessed May 11, 200730. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: in vivo drug metabolism/drug interaction studies – study design, data analysis, and recommendations for dosing and labeling. Available at: http://www.fda.gov/cder/guidance/2635fnl.htm. Accessed May 11, 2007
   Google Scholar
• Eli Lilly and Company, Study Report H7T-EW-TAAJ31. Eli Lilly and Company, Study Report H7T-EW-TAAJ
   Google Scholar